OUTLOOK THERAPEUTICS INC (OTLK)
US69012T3059 - Common Stock
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom...
Outlook Therapeutics® Streamlines Operations
Full NORSE EIGHT Data Readout Expected January 2025...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic...
Outlook Therapeutics® Announces Executive Leadership Transition
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK). Such...
Notable Wednesday Option Activity: EWCZ, JWN, OTLK
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET...
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical...
RSI Alert: Outlook Therapeutics (OTLK) Now Oversold
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval...
OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024
OTLK stock results show that Outlook Therapeutics beat analyst estimates for earnings per share the third quarter of 2024.
OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Outlook Therapeutics (NASDAQ:OTLK) just reported results for the third quarter ...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMDNORSE EIGHT...
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and...
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc....
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of...
3 Undervalued Gems Set to Soar 1,000% by 2026
Discover the fundamentals behind three undervalued stocks to buy in the oil and gas, advertising, and biotechnology industries.
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment...
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024
OTLK stock results show that Outlook Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Outlook Therapeutics (NASDAQ:OTLK) just reported results for the second quarter...
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™...